Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/67904
DC FieldValueLanguage
dc.contributor.authorChou, F.I.en_US
dc.contributor.authorChung, H.P.en_US
dc.contributor.authorShieh, M.S.en_US
dc.contributor.authorHuang, C.W.en_US
dc.contributor.authorChung, R.J.en_US
dc.contributor.authorLiu, H.M.en_US
dc.contributor.authorYang, J.Y.en_US
dc.contributor.authorChi, C.W.en_US
dc.contributor.authorLin, Y.C.en_US
dc.contributor.authorLu, W.Y.en_US
dc.contributor.authorKa, J.J.en_US
dc.date2003zh_TW
dc.date.accessioned2014-06-11T05:55:55Z-
dc.date.available2014-06-11T05:55:55Z-
dc.identifier.issn0250-7005zh_TW
dc.identifier.urihttp://hdl.handle.net/11455/67904-
dc.description.abstractBackground: Hepatoma, a common cancer in Taiwan. responds poorly to conventional therapies. Boron neutron capture therapy (BNCT) may provide a promising approach for hepatoma therapy. In this study, a pharmaceutical composition, phenylboric acid derivative entrapped lipiodol (PBAD-lipiodol), was synthesized and characterized. In vitro study was used for evaluation of PRAD-lipiodol for the BNCT of hepatoma. Materials and Methods: a Track observation was used to identify the boron compound in the TLC plate and to evidence the uniform distribution of boron in the PBAD-lipiodol. Inductively coupled plasma-atomic emission spectroscopy and neutron activation analysis were used to determine the concentrations of boron and lipiodol, respectively. Human hepatoma HepG2 cells were used for in vitro experiments. A Nomarski optical microscope was used to investigate the uptake of PBAD-lipiodol globules in individual hepatoma cells. Results: PBAD-lipiodol was stable in human serum. The boron source, PBAD, was uniformly distributed in PBAD-lipiodol. Many of the PBAD-lipiodol globules were internalized and retained in HepG2 cells, and the boron concentration of HepG2 cells reached 269 ppm after 72 hours of PBAD-lipiodol treatment. Conclusion: In vitro studies revealed that PBAD-lipiodol could deliver a therapeutically effective amount of PBAD as a boron source for the BNCT of hepatoma. PBAD-lipiodol is a potential new boron drug for the BNCT of hepatoma.en_US
dc.language.isoen_USzh_TW
dc.relationAnticancer Researchen_US
dc.relation.ispartofseriesAnticancer Research, Volume 23, Issue 5A, Page(s) 3955-3963.en_US
dc.subjecthepatomaen_US
dc.subjectneutron capture therapyen_US
dc.subjectPBAD-lipiodolen_US
dc.subjectalpha tracken_US
dc.subjecthepatocellular-carcinomaen_US
dc.subjectarterial chemoembolizationen_US
dc.subjectsodiumen_US
dc.subjectborocaptateen_US
dc.subjectenhanced survivalen_US
dc.subjectliver-tumorsen_US
dc.subjectboronophenylalanineen_US
dc.subjectmelanomaen_US
dc.subjectdeliveryen_US
dc.subjectcanceren_US
dc.subjectchemistryen_US
dc.titleSynthesis and in vitro evaluation of the phenylboric acid derivative entrapped lipiodol in boron neutron capture therapy for hepatomaen_US
dc.typeJournal Articlezh_TW
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en_US-
item.fulltextno fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
Appears in Collections:期刊論文
Show simple item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.